A
VRDN icon

AlphaQuest’s Viridian Therapeutics VRDN Stock Holding History

AlphaQuest’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,847
Closed -$618K – 2037
2025
Q4 		$618K Buy
19,847
+2,202
+12% +$60.4K 0.03% 672
2025
Q3 		$381K Buy
17,645
+16,662
+1,695% +$301K 0.02% 990
2025
Q2 		$13.7K Sell
983
-1,812
-65% -$24.6K ﹤0.01% 1832
2025
Q1 		$37.7K Hold
2,795
– – ﹤0.01% 1584
2024
Q4 		$53.6K Buy
2,795
+1,519
+119% +$33K 0.01% 1274
2024
Q3 		$29K Sell
1,276
-4,780
-79% -$78.1K ﹤0.01% 1482
2024
Q2 		$78.8K Buy
6,056
+4,692
+344% +$65K 0.01% 992
2024
Q1 		$23.9K Buy
+1,364
New +$26.4K ﹤0.01% 1018

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AlphaQuest's VRDN Position: Q1 2026 in Review

AlphaQuest sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 19,847 shares — an estimated $618K sold.

AlphaQuest first reported a position in VRDN in Q1 2024 and held it in 8 quarters. The position peaked at $618K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • AlphaQuest reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 19,847 Viridian Therapeutics shares in Q1 2026, an estimated $618K.
  • AlphaQuest first reported a position in Viridian Therapeutics in Q1 2024 and held it in 8 quarters.
  • AlphaQuest's Viridian Therapeutics position peaked at $618K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.